Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer
(Thomson Reuters ONE) -
PRESS RELEASE: 7 June 2017, 07:00 CEST
MRC Technology and Biocartis initiate development of liquid biopsy test for
breast cancer
Partnership aimed at the development of molecular diagnostic assays on
Biocartis' fully automated Idylla(TM) platform
London (UK) / Mechelen (Belgium), 7 June 2017 - MRC Technology ('MRCT'), a
medical research charity, and Biocartis Group NV ('Biocartis' or the 'Company'),
an innovative molecular diagnostics company (Euronext Brussels: BCART), today
announced a partnership to develop selected molecular diagnostic tests for use
on Biocartis' fully automated Idylla(TM) platform. MRCT aims to move promising
medical research forward into patient treatments and diagnostics and has been
involved in helping deliver a number of therapies including Keytruda®
(pembrolizumab, marketed by MSD) which is an important immunotherapy treatment
for various cancers.
Under the terms of the agreement, Biocartis and MRCT will jointly develop
selected molecular diagnostic tests for use on the fully automated Idylla(TM)
platform. For each selected test, MRCT will act as a development contractor,
whereas Biocartis will be responsible for the commercialization of the tests
under its own label. Financial details of the partnership are not disclosed.
The first test to be developed under the partnership is a liquid biopsy test
aimed at monitoring of metastatic breast cancer patients for resistance to
hormone therapy. This is an important first step in the breast cancer menu that
Biocartis is developing, and has a clear strategic fit within the Company's
focus on liquid biopsy testing.
One in eight women is diagnosed with breast cancer in her lifetime, according to
the World Health Organization. This makes it the most common cancer among women
worldwide[1] but early diagnosis can improve the survival rate[2]. Consequently,
breast cancer is currently the largest cancer diagnostics market in the
world[3], expected to account for USD 13.1bn by 2020[4]. As such, it represents
an important segment for Biocartis to enter, next to its current focus on
melanoma, lung and colorectal cancer.
Erwin Sablon, Head of R&D and Alliance Management at Biocartis, commented:
"Building partnerships with third parties to accelerate the expansion of our
menu of molecular diagnostic tests is a key element in our strategy. We are very
pleased to be partnering with MRCT, an organization that has clearly shown the
ability to convert promising medical research into solutions for patients. MRCT
has an experienced team in place and we are confident that together we can
successfully develop a range of high quality tests for the Idylla(TM) platform,
beginning with this first test for breast cancer."
Michael A. Dalrymple, PhD, MBA, Director, Diagnostics & Science Foresight MRCT,
reacted: "We are excited to partner with Biocartis on test development for the
Idylla(TM) platform, which we believe can impact the way molecular diagnostics
for oncology is done today. This resonates well with our focus of translating
medical innovation into viable and accessible treatments and diagnostics that
patients can benefit from. Breast cancer has an enormous impact on many lives
every day and we see this assay as an important project to start our partnership
with."
Within its melanoma and colorectal cancer menu, Biocartis already launched three
liquid biopsy assays[5] (available for research use only), detecting a large set
of actionable mutations directly from 1 ml of blood plasma each. The fourth
liquid biopsy assay, the Idylla(TM) ctEGFR Mutation Assay, adding to Biocartis'
lung cancer test menu, is expected to be launched in H2 2017.
-- END ---
More information:
Liezel Tipper
PR & Communications Manager
MRC Technology
email: Liezel.Tipper(at)tech.mrc.ac.uk
tel +44 20 7391 2772
Renate Degrave
Manager Corporate Communications & Investor Relations
Biocartis
e-mail rdegrave(at)biocartis.com
tel +32 15 631 729
mobile +32 471 53 60 64
About MRC Technology
MRC Technology is an independent life science medical research charity committed
to improving positive patient outcomes everywhere. As a champion for human
health, MRC Technology partners with academic, biotechnology, pharmaceutical and
charity organisations to move promising medical research forward into viable and
accessible patient treatments. As a self-funded charity, income is reinvested to
support translating research from the bench to patient. MRC Technology offers
commercialization and IP management skills and diagnostic and drug discovery
expertise, specializing in small molecules and therapeutic antibodies.
www.mrctechnology.org. MRC Technology's work has helped to develop four drugs
(Keytruda(®), Actemra(®), Tysabri(®) and Entyvio(®)) and a test for
antimicrobial resistance.
About Biocartis
Biocartis (Euronext Brussels: BCART) is an innovative molecular diagnostics
(MDx) company providing next generation diagnostic solutions aimed at improving
clinical practice for the benefit of patients, clinicians, payers and industry.
Biocartis' proprietary MDx Idylla(TM) platform is a fully automated sample-to-
result, real-time PCR (Polymerase Chain Reaction) system that offers accurate,
highly reliable molecular information from virtually any biological sample in
virtually any setting. Biocartis launched the Idylla(TM) platform in September
2014. Biocartis is developing and marketing a rapidly expanding test menu
addressing key unmet clinical needs in oncology and infectious diseases. These
areas represent respectively the fastest growing and largest segments of the MDx
market worldwide. Today, Biocartis offers nine oncology tests and two infectious
disease tests. More information: www.biocartis.com. Press Photo Library
available here. Follow us on Twitter: (at)Biocartis_.
Certain statements, beliefs and opinions in this press release are forward-
looking, which reflect the Company or, as appropriate, the Company directors'
current expectations and projections concerning future events such as the
Company's results of operations, financial condition, liquidity, performance,
prospects, growth, strategies and the industry in which the Company operates. By
their nature, forward-looking statements involve a number of risks,
uncertainties, assumptions and other factors that could cause actual results or
events to differ materially from those expressed or implied by the forward-
looking statements. These risks, uncertainties, assumptions and factors could
adversely affect the outcome and financial effects of the plans and events
described herein. A multitude of factors including, but not limited to, changes
in demand, competition and technology, can cause actual events, performance or
results to differ significantly from any anticipated development. Forward-
looking statements contained in this press release regarding past trends or
activities are not guarantees of future performance and should not be taken as a
representation that such trends or activities will continue in the future. In
addition, even if actual results or developments are consistent with the
forward-looking statements contained in this press release, those results or
developments may not be indicative of results or developments in future periods.
As a result, the Company expressly disclaims any obligation or undertaking to
release any update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these forward-looking
statements are based. Neither the Company nor its advisers or representatives
nor any of its subsidiary undertakings or any such person's officers or
employees guarantees that the assumptions underlying such forward-looking
statements are free from errors nor does either accept any responsibility for
the future accuracy of the forward-looking statements contained in this press
release or the actual occurrence of the forecasted developments. You should not
place undue reliance on forward-looking statements, which speak only as of the
date of this press release.
--------------------------------------------------------------------------------
[1] Source: World Cancer Research Fund International,
http://www.wcrf.org/int/cancer-facts-figures/data-specific-cancers/breast-
cancer-statistics, last consulted on 17 May 2017.
[2] Source: http://www.nationalbreastcancer.org/breast-cancer-facts, last
consulted on 15 May 2017.
[3] Source: GrandView Research, "Cancer Diagnostics Market Analysis By Type
(Laboratory Tests, Genetic Tests, Imaging, Endoscopy), By Application (Breast,
Lung, Liver, Cervical, Colorectal, Skin), By Region, And Segment Forecasts,
2014 - 2025", http://www.grandviewresearch.com/industry-analysis/cancer-
diagnostics-market, last consulted on 15 May 2017.
[4] Source: MarketsandMarkets, "Cancer Diagnostics Market by Technology (ELISA,
ELFA, PCR, NGS, Immunohistochemistry, Microarray, Imaging (MRI, CT, PET,
Ultrasound, Mammography), Biopsy), by Application (Breast Cancer, Lung Cancer,
Colorectal Cancer, Melanoma) - Forecast to 2020", 2015.
[5] The Idylla(TM) ctBRAF Mutation Assay, the Idylla(TM) ctKRAS Mutation Assay
and the Idylla(TM) ctNRAS-BRAF-EGFR S492R Mutation Assay are Research Use Only
(RUO) and not for use in diagnostic procedures.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Biocartis Group NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="First Global Signs Agreement For Mobile Wallet Deployment in 19 African CountriesDatum: 07.06.2017 - 07:00 Uhr
Sprache: Deutsch
News-ID 546627
Anzahl Zeichen: 11179
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 316 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Biocartis Group NV: MRC Technology and Biocartis initiate development of liquid biopsy test for breast cancer"
steht unter der journalistisch-redaktionellen Verantwortung von
Biocartis Group NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
